Table 5 Phase 1 and early phase 1 small molecule inhibitors/modulators for RRMM, as of December 31, 2020, with study start date after January 1, 2019
From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Target pathway | Product name (NCT) | Study sponsor | Estimated enrollment | Country |
|---|---|---|---|---|
Adenosine-2A receptor | Ciforadenant (CPI-444) (NCT04280328) | Corvus | 28 | United States |
Arginase | INCB001158 (NCT03837509) | Incyte | 98 | United States, Germany, Spain |
Bcl-2/Bcl-xL (apoptosis regulator) | AZD0466 (NCT04214093) | AstraZeneca | 102 | United States |
Bcl-2 | S65487 (NCT03755154) | Institut de Recherches Internationales Servier | 60 | Australia, France, Spain, United Kingdom |
BTK (Bruton’s tyrosine kinase) | Ibrutinib (NCT03702725) | Alliance Foundation | 28 | United States |
Cereblon E3 ubiquitin ligase (CELMoD – protein homeostasis) | CC-92480 (NCT03989414) | Celgene | 215 (includes NDMM) | United States, Canada, Denmark, Finland, Spain, United Kingdom |
IL-15 receptor (cytokine signaling) | NKTR-255 (NCT04136756) | Nektar | 87 | United States |
IRF4 (lymphocyte transcriptional factor) | ION251 (NCT04398485) | Ionis | 80 | United States |
JAK (Janus kinase/tyrosine kinase) | Ruxolitinib (NCT03773107) | Incyte | 48 | United States |
LMP7 (proteasome complex subunit) | M3258 (NCT04075721) | EMD Serono | 48 | United States, France |
Mcl-1 (apoptosis control) | ABBV-467 (NCT04178902) | AbbVie | 54 | United States, Australia, France, Israel, Japan, Spain, Taiwan |
Mcl-1 | PRT1419 (NCT04543305) | Prelude | 36 | United States |
NEDD8 (ubiquitin-like protein) | Pevonedistat (NCT03770260) | National Cancer Institute | 66 | United States |
p300/CBP (transcriptional coactivating proteins) | CCS1477 (NCT04068597) | CellCentric | 90 | United Kingdom |
Proteasome inhibitor | TQB3602 (NCT04275583) | Chia Tai Tianqing | 40 | China |
RAD51 (DNA repair protein) | CYT-0851 (NCT03997968) | Cyteir | 165 | United States |
S100A9 (regulation of immune response and inflammation) | Tasquinimod (NCT04405167) | University of Pennsylvania | 54 | United States |
TIGIT (T and NK cell immune receptor) | COM902 (NCT04354246) | Compugen | 45 | United States |
TIGIT | Tiragolumab (NCT04045028) | Genentech | 52 | United States, Korea |
Anti-TIGIT and anti-LAG | BMS-986016 and BMS-986207 (NCT04150965) | Multiple Myeloma Research Consortium | 104 | United States |
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) | Eftozanermin alfa (ABBV-621) (NCT04570631) | AbbVie | 40 | United States, France, German, Italy, Japan, Spain |
Specific targeted therapy based on mutations uncovered with genomic studies | MyDRUG (NCT03732703) | Multiple Myeloma Research Consortium | 228 | United States |
Specific targeted therapy based on mutations uncovered with genomic studies | SMMART PRIME (NCT03878524) | Oregon Health and Science University | 40 | United States |